One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Silence Therapeutics plc
SLN · NGM · Healthcare · Biotechnology
Current price
$19.77
52-week range
$4.19 - $19.86
Market cap
$1.23B
Balance sheet
Healthy
-2,072.21x Concerning
Net cash $71.94M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 10.0% last year.
- Risk Operating margin compressed from -281.9% to -10475.6% over 3 years.
- Risk Return on equity was -90.4% last year — the company lost money on shareholders' equity.
What this company does
Silence Therapeutics plc
Silence Therapeutics is a science company that creates medicines using a special technology called siRNA (small interfering ribonucleic acid) to turn off specific faulty genes that cause diseases like blood disorders and heart problems. The money they make comes from developing these new medicines and potentially partnering with bigger drug companies to get them to patients, which is important for their future growth.
How the company got here
Silence Therapeutics plc, originally founded in 1994 as SR Pharma plc, has evolved significantly in the biotechnology landscape. The company officially changed its name to Silence Therapeutics in May 2007, reflecting a strategic shift towards its core focus. This pivot centered on the discovery and development of innovative molecules that use short interfering ribonucleic acid (siRNA) to precisely target and reduce the expression of specific genes. This approach aims to address diseases in areas like blood disorders (hematology), heart conditions (cardiovascular), and rare genetic conditions.
What it actually does
Silence Therapeutics is a biotechnology company focused on creating new medicines using a technology called siRNA. Think of siRNA as a tiny messenger molecule that can tell specific genes in your body to quiet down. By doing this, the company aims to treat diseases that are caused by genes acting in ways they shouldn't. Their work involves developing these siRNA-based therapies for serious medical conditions, with a particular emphasis on diseases affecting blood, the heart, and those that are rare.
Divesiran (SLN124)
Divesiran, also known as SLN124, is one of Silence Therapeutics' key drug candidates. This therapy is designed to target specific genes involved in polycythemia vera, a condition where the body makes too many red blood cells. The company is currently in Phase 2 development for Divesiran, which means it's being tested in a larger group of patients to see how effective and safe it is. This segment represents a significant part of the company's efforts in developing treatments for blood-related disorders.
Zerlasiran (SLN360)
Zerlasiran, or SLN360, is another important therapeutic candidate from Silence Therapeutics. This drug is being developed to treat cardiovascular diseases, specifically those linked to high levels of a substance called lipoprotein(a). High levels of lipoprotein(a) are a known risk factor for heart attacks and strokes. By targeting this specific marker, Zerlasiran aims to reduce the risk of these serious cardiovascular events, representing a key focus area for the company in tackling heart health.
Other Pipeline Candidates
Beyond Divesiran and Zerlasiran, Silence Therapeutics is exploring several other potential treatments. These include SLN548 for kidney diseases driven by the complement system (a part of the immune system), SLN312 and SLN365 for dyslipidemia and hypercholesterolemia (conditions related to abnormal levels of fats in the blood), and SLN098 for obesity. These diverse candidates showcase the company's broad application of its siRNA technology across various disease areas, aiming to address unmet medical needs.
What management is betting on now
Silence Therapeutics' management is primarily focused on advancing its pipeline of siRNA-based therapeutics through clinical trials and towards potential market approval. The key strategic priority is to successfully develop and demonstrate the efficacy and safety of its lead candidates like Divesiran and Zerlasiran in treating their respective target diseases. By progressing these programs, the company aims to validate its technology platform and secure partnerships or approvals that could lead to new medicines for patients with significant unmet medical needs in hematology, cardiovascular diseases, and rare conditions.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-25.67M
FY2024 Q4
$-27.54M
FY2025 Q1
$-12.31M
FY2025 Q2
$-21.83M
FY2025 Q3
$-10.89M
FY2025 Q4
$-17.29M
FY2026 Q1
$-15.60M
FY2026 Q2
$1.52M
Revenue
$0.00
Net income
$-12.27M
Diluted EPS
-0.09
Operating cash flow
$1.52M
Free cash flow
$1.52M
Fetching…
Sources
Revenue
$422.00K
Net income
$-14.96M
Diluted EPS
-0.11
Operating cash flow
$-15.60M
Free cash flow
$-15.60M
Fetching…
Sources
Revenue
$34.00K
Net income
$-11.77M
Diluted EPS
-0.09
Operating cash flow
$-17.29M
Free cash flow
$-17.29M
Fetching…
Sources
Revenue
$159.00K
Net income
$-20.96M
Diluted EPS
-0.15
Operating cash flow
$-10.89M
Free cash flow
$-10.89M
Fetching…
Sources
Revenue
$224.00K
Net income
$-27.35M
Diluted EPS
-0.19
Operating cash flow
$-21.78M
Free cash flow
$-21.83M
Fetching…
Sources
Revenue
$142.00K
Net income
$-28.53M
Diluted EPS
-0.20
Operating cash flow
$-12.31M
Free cash flow
$-12.31M
Fetching…
Sources
Revenue
$25.30M
Net income
$12.30M
Diluted EPS
0.08
Operating cash flow
$-27.48M
Free cash flow
$-27.54M
Fetching…
Sources
Revenue
$1.50M
Net income
$-35.54M
Diluted EPS
-0.25
Operating cash flow
$-25.61M
Free cash flow
$-25.67M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $19.77
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $71.9M - more cash than debt. Interest coverage -2072.2x.
Net debt
$-71.94M
Interest coverage
-2,072.21x
Silence Therapeutics plc's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SLN
BASELINE
Silence Therapeutics plc
Total debt $112.00K Interest coverage -2,072.21x This is the baseline the peer rows are being compared against.
Total debt $1.38B Interest coverage 1.10x This peer still has a real interest-payment cushion, while SLN does not.
Total debt $3.59M Interest coverage -8.11x Neither company has much profit cushion over interest right now.
Total debt $278.20M Interest coverage -6.38x Neither company has much profit cushion over interest right now.
Total debt $30.66M Interest coverage -11.20x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SLN
1 Reward
2 Risks
Rewards
-
Revenue grew 10.0% last year.
Risks
-
Operating margin compressed from -281.9% to -10475.6% over 3 years.
-
Return on equity was -90.4% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-52.01x
P/B
24.28x
P/S
1,999.09x
EV/EBITDA
-13.51x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
85.9%
Operating margin
-10,475.6%
Net margin
0.0%
ROE
-90.4%
ROA
-29.6%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
7.42x
Quick ratio
6.40x
Total debt
$112.00K
Total cash
$72.05M
Growth
How the business has been compounding
Revenue TTM
$615.00K
Revenue 5Y CAGR
-70.4%
EPS TTM
-1.29
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-42.26M
Free CF TTM
$-62.33M
FCF margin
-10,134.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—